RdRP is the target of inhibitors like remdesivir (178), galidesivir (179), ribavirin (180), favipiravir (181), and EIDD‐2801 (182). These molecules have shown promise for the treatment of COVID‐19 patients. 87 ,  216 ,  217 ,  218  (For structures and biological data see Figure 38)